Datta Niloy R, Rogers Susanne, Klingbiel Dirk, Gómez Silvia, Puric Emsad, Bodis Stephan
a Centre for Radiation Oncology , KSA-KSB, Kantonsspital Aarau , Aarau , Switzerland ;
b Swiss Group for Clinical Cancer Research (SAKK) , Coordinating Centre , Bern , Switzerland ;
Int J Hyperthermia. 2016 Nov;32(7):809-21. doi: 10.1080/02656736.2016.1195924. Epub 2016 Aug 14.
A systematic review with conventional and network meta-analyses (NMA) was conducted to examine the outcomes of loco-regional hyperthermia (HT) with radiotherapy (RT) and/or chemotherapy (CT) in locally advanced cervix cancer, IIB-IVA (LACC).
A total of 217 abstracts were screened from five databases and reported as per PRISMA guidelines. Only randomised trials with HT and RT ± CT were considered. The outcomes evaluated were complete response (CR), long-term loco-regional control (LRC), patients alive, acute and late grade III/IV toxicities.
Eight articles were finally retained. Six randomised trials with HTRT (n = 215) vs. RT (n = 212) were subjected to meta-analysis. The risk difference for achieving CR and LRC was greater by 22% (p < .001) and 23% (p < .001), respectively, with HTRT compared to RT. A non-significant survival advantage of 8.4% with HTRT was noted with no differences in acute or late toxicities. The only HTCTRT vs. RT trial documented a CR of 83.3% vs. 46.7% (risk difference: 36.7%, p = .001). No other end points were reported. Bayesian NMA, incorporating 13 studies (n = 1000 patients) for CR and 12 studies for patients alive (n = 807 patients), comparing HTCTRT, HTRT, CTRT and RT alone, was conducted. The pairwise comparison of various groups showed that HTRTCT was the best option for both CR and patient survival. This was also evident on ranking treatment modalities based on the "surface under cumulative ranking" values.
In LACC, HTRT demonstrates a therapeutic advantage over RT without significant acute or late morbidities. On NMA, HTCTRT appears promising, but needs further confirmation through prospective randomised trials.
进行一项系统评价及传统和网状Meta分析(NMA),以研究局部晚期宫颈癌(IIB-IVA期,LACC)中局部区域热疗(HT)联合放疗(RT)和/或化疗(CT)的疗效。
从五个数据库中筛选出共217篇摘要,并按照PRISMA指南进行报告。仅纳入了采用HT联合RT±CT的随机试验。评估的结局包括完全缓解(CR)、长期局部区域控制(LRC)、存活患者、急性和晚期III/IV级毒性反应。
最终保留了8篇文章。对6项HTRT(n = 215)与RT(n = 212)的随机试验进行了Meta分析。与RT相比,HTRT实现CR和LRC的风险差异分别高出22%(p <.001)和23%(p <.001)。观察到HTRT有8.4%的非显著生存优势,急性或晚期毒性反应无差异。唯一的HTCTRT与RT试验记录的CR分别为83.3%和46.7%(风险差异:36.7%,p =.001)。未报告其他终点。进行了贝叶斯NMA,纳入了13项关于CR的研究(n = 1000例患者)和12项关于存活患者的研究(n = 807例患者),比较了HTCTRT、HTRT、CTRT和单纯RT。各亚组的两两比较表明,HTRTCT对CR和患者生存都是最佳选择。基于“累积排序曲线下面积”值对治疗方式进行排序时,这一点也很明显。
在LACC中,HTRT显示出优于RT的治疗优势,且无显著的急性或晚期并发症。在NMA中,HTCTRT似乎很有前景,但需要通过前瞻性随机试验进一步证实。